Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Sök Study Connect
  • NCT04817007

Active, Not Recruiting

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) - CA011-023

Uppdaterad: 19 februari, 2025   |   ClinicalTrials.gov

Utskriftsvänlig sammanfattning

ÄR DU INTRESSERAD AV DEN HÄR PRÖVNINGEN?
Skriv ut den här sidan och broschyren om kliniska prövningar som hjälp under samtalet med din läkare.
Använd broschyren ”Om att delta i en klinisk prövning” för att få vägledning om deltagandeprocessen i en klinisk prövning. Förstå de viktiga faktorerna som man måste tänka på före ett beslut och få hjälp med att formulera frågor till studiepersonalen.
Skriv ut den här sidan CA011-023
Ladda ned broschyren ”Om att delta i en klinisk prövning”

VÄLJ SPRÅK

Information om prövningen

  • Phase 1

    Fas

  • Kön

  • 18+

    Åldersintervall

  • Active, Not Recruiting

Behandlingsalternativ

Studiegrupper
TILLDELAD BEHANDLING
Experimental: Part 1A: BMS-986158 + Ruxolitinib
Drug: BMS-986158, Ruxolitinib
Experimental: Part 1B: BMS-986158 + Fedratinib
Drug: BMS-986158, Fedratinib
Experimental: Part 2A: BMS-986158 + Ruxolitinib
Drug: BMS-986158, Ruxolitinib
Experimental: Part 2A2 Add-On: BMS-986158 + Ruxolitinib
Drug: BMS-986158, Ruxolitinib
Experimental: Part 2A3: BMS-986158 + Ruxolitinib
Drug: BMS-986158, Ruxolitinib
Experimental: Part 2B1: BMS-986158 + Fedratinib
Drug: BMS-986158, Fedratinib
Experimental: Part 2B2: BMS-986158 Mono and/or (BMS-986158 + Fedratinib), if applicable

Viktiga kriterier för deltagandet

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Diagnosis of primary myelofibrosis (PMF), post-essential thrombocythemia (ET) or post-polycythemia vera (PV) myelofibrosis - Treatment-related toxicities from prior therapy resolved to Grade 1 or pre-treatment baseline or determined to be irreversible prior to study treatment - Must agree to follow specific methods of contraception, if applicable Exclusion Criteria: - Women who are pregnant or breastfeeding at screening - Any significant acute or uncontrolled chronic medical illness Other protocol-defined inclusion/exclusion criteria apply

Vi rekommenderar att du kontaktar BMS för att rapportera biverkningar.
Biverkningar (oönskade händelser) och andra rapporterbara händelser definieras här
För att rapportera biverkningar (oönskade händelser) eller reklamera ett läkemedel: Medicinsk information

466-SE-2100058